Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Coffee and tea: a new weapon against fatty liver?

NCT ID NCT07768956

Disease control Sponsor: Okan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time

Summary

This study tests whether adding Turkish coffee or green tea to a Mediterranean diet can reduce liver fat in people with non-alcoholic fatty liver disease (NAFLD). Participants will follow a 12-week diet plan and drink either Turkish coffee twice daily, green tea three times daily, or no extra beverage. Researchers will measure changes in liver fat, liver enzymes, and body measurements to see if these drinks offer extra benefits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Turkish coffee, green tea, and a Mediterranean diet
What this could lead to
If this works, it could point to simple dietary additions that help manage fatty liver disease and improve liver health.
What could go wrong
This is a small, early-stage trial, so results may not apply broadly. The effects could be modest, and the study doesn't test long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

47 people

The number who actually took part.

Started

Sep 2024

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants aged 19-65 years with a diagnosis of non-alcoholic fatty liver disease (NAFLD). * Not using medications for diabetes, dyslipidemia, or rheumatoid arthritis. * Not using dietary supplements. * No dietary program followed within the previous month. * No severe psychiatric disorders. * Willingness to participate in the study and provide informed consent. Exclusion Criteria: * Presence of diabetes, dyslipidemia, or rheumatoid arthritis. * Alcohol consumption. * Positive hepatitis B surface antigen (HBsAg), hepatitis C positivity, autoimmune hepatitis, liver cirrhosis, toxic hepatitis, or alanine aminotransferase (ALT) levels ≥10 times the upper limit of normal. * Presence of liver malignancy or hepatic decompensation. * Use of systemic corticosteroids or methotrexate within the previous 6 months. * Pregnancy or lactation. * Regular use of dietary supplements. * Following a dietary program within the previous month. * Presence of severe psychiatric disorders. * High daily consumption of tea and coffee.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-alcoholic fatty liver disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-alcoholic fatty liver disease

Contacts and locations

Locations

  • Istanbul Dr. Lutfi Kirdar City Hospital

    Istanbul, Istanbul, 34865, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.